Navigation Links
Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
Date:12/4/2007

Results Set Stage for Development of Sustainable, Organic Livestock and

Fish Feeds

BOCA RATON, Fla., Dec. 4 /PRNewswire-FirstCall/ -- Neptune Industries, Inc. (OTC Bulletin Board: NPDI), a next generation aquaculture technology company with diversified interests in production system technology, food science, sustainable seafood, waste-to-energy production, and related natural and organic food products, announced today that Phase II trials on the Company's Ento-Protein(TM) research has been successfully completed.

The completion of Phase II trials represents the pivotal milestone in developing a viable dietary protein alternative in the $7 billion dollar market for fishmeal. Phase I selected four species of suitable insects based upon a myriad of key production and nutritional parameters. The industry has been focused on vegetable-based alternatives, however these proteins are not well digested by carnivorous fish. Phase II trials proved that fish fed a diet containing Ento-Protein(TM) actually tasted better than those fed fishmeal. The final trial, Phase III, will be used to select the proper blend of insects to achieve the fastest growth rate and optimum digestibility in farm raised fish. The Company anticipates completing the Phase III trial in the first quarter of 2008, constructing its first pilot production facility, and bringing product to market by year end.

The Phase II trials compared juvenile hybrid striped bass fed on a typical fishmeal-based diet, with those fed with Neptune's Ento-Protein(TM), consisting of 100% of the fishmeal portion of their diet. Phase II trial results indicated that the fish fed with Ento-Protein(TM) did not change their behavioral patterns. A panel of sensory experts that evaluated the trials indicated that they favored the fish fed with Ento-Protein(TM) over those fish fed with traditional fishmeal.

Ento-Protein(TM) is a patent-pending high protein fishmeal derived from the controlled, mass production of select insect species, for use in fish and livestock diets. The percentage of fishmeal used in fish feed has declined due to a steady rise in price. According to a key report by Pike and Barlow the market for fish feed is expect to grow from 19.5 million metric tons in 2003 to 37.2 million metric tons in 2010. This market could widen substantially, with the addition of a sustainable, high protein alternative such as Ento- Protein(TM).

Neptune Industries has been involved in a cooperative research relationship with Mississippi State University since January 2007. Phase II trials were a collaborative effort between the Departments of Entomology, Wildlife and Fisheries, and Food Science and Technology.

Dr. Lou D'Abramo, Professor, Department of Wildlife and Fisheries at Mississippi State stated, "In the recent feeding trial, the Ento-Protein(TM) replaced fishmeal as an ingredient of a sustainable diet for hybrid striped bass. No differences in feeding behaviors were found when comparing the control group with the test group. This observation represents an important positive step in realizing the potential for Ento-Protein(TM) in becoming an effective replacement for fishmeal in carnivorous fish diets."

Dr. Patti Coggins, Director, Dept. of Food Science and Technology at Mississippi State commented, "The results of our recent sensory evaluation comparing the taste, texture, aroma, and appearance of the fish on the Ento- Protein(TM) feeding trials were very encouraging. A sensory panel of experts actually favored the flavor of the fish fed with the Ento-Protein(TM) diet over fish on the traditional fishmeal based diets. Also worth mentioning was the break through observation that both the raw and cooked fish had less of a 'fishy' aroma due to the Ento-Protein(TM) feeding. This could be seen as a positive attribute for many potential consumers and positively impact the way alternatives for fish feed are viewed."

President of Neptune Industries, Ernest Papadoyianis, stated, "We believe that our Phase II results set the stage for providing a global solution to the protein shortage that has been plaguing the global aquaculture market. Our research team at Mississippi State University is comprised of some of the most experienced, knowledgeable and recognized individuals in their respective fields. Their unanimous positive feedback to date has further fueled our excitement for the commercialization potential of Ento-Protein(TM). We look forward to commencing our Phase III trials for growth and digestibility very soon."

About Neptune Industries:

Based in Boca Raton, Florida, Neptune Industries, Inc. has developed a scalable, modular aquaculture technology called Aqua-Sphere(TM) and Aqua- Cell(TM) that successfully address the environmental concerns of most aquaculture operations by controlling and recycling all waste products, while insuring the production of the highest quality fish at an affordable price. The company currently operates the Blue Heron Aqua Farms in Florida City, FL and is a leading producer of hybrid striped bass, which it markets internationally as Everglades Striped Bass(TM). The company's current production at its Blue Heron farm, and future production with Aqua-Sphere(TM) System technology are intended to target the organic market as soon as organic certification of farm-raised seafood becomes available. The Company is also in development of an advanced dietary nutritional component called Ento- Protein(TM). Ento-Protein(TM) is a high quality, sustainable protein derived from insects, and is intended to be a replacement for the scarce fishmeal now used in fish and animal diets. For further information, please visit the Company's website at: http://www.neptuneindustries.net.

Contact:

Investor Relations Contact:

Michael Steinberg

Chelsea Holdings, Inc.

1200 S. Federal Hwy., Suite 200

Boca Raton, FL 33431

561-210-8544

Email: info@neptuneindustries.net

Gary Geraci

Equity Performance Group

617-242-1025

Email: Gary@EquityPerfGP.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.


'/>"/>
SOURCE Neptune Industries
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:4/28/2016)... FLINT, Mich. , April 28, 2016 /PRNewswire/ ... transaction . Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... it has signed a definitive agreement to acquire ... Advanced Specialty Pharmacy ("TNH"), a leading specialty pharmacy ... Van Nuys, California . In 2015, ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... The new web-based solution ... physician practices, to better grasp and implement HIPAA’s privacy, security, and data breach ... a well-defined, expert-created path to compliance. HIPAA Institute has positioned itself to be ...
(Date:5/3/2016)... , ... May 03, 2016 ... ... Cruise Lines premiered the state-of-the-art Carnival Vista – the line’s largest cruise ... The Cruise Web has created an infographic spotlighting the Carnival Vista ...
(Date:5/2/2016)... ... May 03, 2016 , ... ... approved sSOIP telemedicine stethoscope software that enables the stethoscope stream to go over ... and works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software ...
(Date:5/2/2016)... ... May 02, 2016 , ... Those ... rehabilitation center can find some useful information in a new video released by ... This video, which can be viewed on the Serenity Recovery YouTube channel, examines ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Beryl ... Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and ... representing international (non-US) based authors, the third volume of PXJ continues to expand ...
Breaking Medicine News(10 mins):